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FHL2 inhibits the activated osteoclast
in a TRAF6-dependent manner
Shuting Bai,1 Hideki Kitaura,1 Haibo Zhao,1 Ju Chen,2 Judith M. Müller,3 Roland Schüle,3
Bryant Darnay,4 Deborah V. Novack,1,5 F. Patrick Ross,1 and Steven L. Teitelbaum1
1Department

of Pathology, Washington University School of Medicine, St. Louis, Missouri, USA. 2Department of Medicine, School of Medicine,
University of California at San Diego, La Jolla, California, USA. 3Universitäts-Frauenklinik und Zentrum für Klinische Forschung,
Klinikum der Universität Freiburg, Freiburg, Germany. 4Department of Experimental Therapeutics, The University of Texas,
MD Anderson Cancer Center, Houston, Texas, USA. 5Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.

TNF receptor–associated factor 6 (TRAF6) associates with the cytoplasmic domain of receptor activator of NF-κB
(RANK). This event is central to normal osteoclastogenesis. We discovered that TRAF6 also interacts with
FHL2 (four and a half LIM domain 2), a LIM domain–only protein that functions as a transcriptional coactivator or corepressor in a cell-type–specific manner. FHL2 mRNA and protein are undetectable in marrow macrophages and increase pari passu with osteoclast differentiation in vitro. FHL2 inhibits TRAF6-induced NF-κB
activity in wild-type osteoclast precursors and, in keeping with its role as a suppressor of TRAF6-mediated
RANK signaling, TRAF6/RANK association is enhanced in FHL2–/– osteoclasts. FHL2 overexpression delays
RANK ligand–induced (RANKL-induced) osteoclast formation and cytoskeletal organization. Interestingly,
osteoclast-residing FHL2 is not detectable in naive wild-type mice, in vivo, but is abundant in those treated
with RANKL and following induction of inflammatory arthritis. Reflecting increased RANKL sensitivity,
osteoclasts generated from FHL2–/– mice reach maturation and optimally organize their cytoskeleton earlier
than their wild-type counterparts. As a consequence, FHL2–/– osteoclasts are hyperresorptive, and mice lacking
the protein undergo enhanced RANKL and inflammatory arthritis–stimulated bone loss. FHL2 is, therefore,
an antiosteoclastogenic molecule exerting its effect by attenuating TRAF6-mediated RANK signaling.
Introduction
Osteoclasts are polykaryons unique in their capacity to resorb
bone (1). They are derived from monocyte/macrophage precursors
that assume the osteoclast phenotype under the aegis of the key
osteoclastogenic cytokine, receptor activator of NF-κB (RANK)
ligand (RANKL) (2). RANKL and its receptor RANK (3) are respective members of the TNF superfamilies of cytokines and receptors,
but RANKL enjoys structural features that endow it with its osteoclastogenic properties (4).
RANK, like other members of the TNF family of receptors, mediates its intracellular signals via a group of proteins known as TNF
receptor–associated factors (TRAFs) (5). While a number of TRAFs
are promiscuous in associating with TNF family receptors, only
RANK and CD40 recognize and signal through TRAF6 (6, 7). The
fact that TRAF6 plays an essential role in osteoclastogenesis is
established by the presence of severe osteopetrosis in mice deleted
of the adaptor protein (8, 9). Thus, delineation of the bone resorptive process requires an understanding of the means by which
TRAF6 mediates RANK-induced osteoclastogenesis.
The LIM domain represents a protein motif characterized by
double zinc fingers (10). It is a component of an array of molecules, many of which serve as adapters and modifiers of proteinprotein interactions. The four and a half LIM domain (FHL) subNonstandard abbreviations used: ACT, activator of CREM in testis; BMM, bone
marrow macrophage; CREM, cAMP response element modulator protein; FHL, four
and a half LIM domain; RANK, receptor activator of NF-κB; RANKL, RANK ligand;
TRACP 5b, tartrate-resistant acid phosphatase 5b; TRAF, TNF receptor–associated
factor; TRAP, tartrate-resistant acid phosphatase.
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family of these proteins consist of 5 members, FHL1, -2, -3, and -4
and activator of CREM (cAMP response element modulator protein) in testis (ACT), each consisting exclusively of LIM domains
(11). FHL proteins are not known to be expressed in bone cells or
participate in skeletal function.
In our exploration of the means by which TRAF6 mediates osteoclastogenesis, we found it associates with FHL2, which is expressed
only in activated osteoclasts in vivo. Furthermore, FHL2, by displacing TRAF6 from RANK, attenuates osteoclast formation and cytoskeletal organization via inhibition of NF-κB. As a consequence,
osteoclastogenesis and bone resorption are accelerated in the face
of FHL2 deficiency. FHL2 therefore represents a physiological regulator of stimulated osteoclast differentiation and skeletal mass.
Results
TRAF proteins interact with FHL2. We initially utilized TRAF4 as
bait in a yeast 2-hybrid system. A mouse embryo cDNA library
was screened and FHL2 revealed itself as an interesting target (not
shown). To determine whether FHL2 also interacts with TRAFs in
mammalian cells, we expressed FLAG-tagged TRAF2, TRAF4, and
TRAF6 and HA-tagged FHL2 in 293T cells. The cells were lysed
and the lysate was immunoprecipitated with anti-FLAG antibody,
then subjected to Western blot with anti-HA antibody. To assess
relative expression of the transfected plasmids, anti-FLAG and
anti-HA immunoblots were generated from equal amounts of
lysates. As seen in Figure 1A, each FLAG-tagged TRAF associates
with FHL2-HA, but TRAF6 does so most effectively, particularly in
light of its abundance relative to TRAFs 2 and 4.
Since TRAF6 is a crucial RANKL/RANK signaling mediator (12),
we turned our attention to its predominant association with FHL2
with the hypothesis that the latter may regulate osteoclast function.
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marrow macrophages (BMMs) in M-CSF and
RANKL. Total RNA was extracted on days 0, 2,
and 4 and RT-PCR performed to detect FHL2
mRNA. While FHL2 mRNA was nondetectable
in BMMs, its expression was incrementally
enhanced in WT cells as they committed to the
osteoclast phenotype (Figure 3A). Similarly,
FHL2 protein appears with osteoclast differentiation (Figure 3B). As expected, neither FHL2
message nor protein is demonstrable in osteoclasts lacking the gene. Establishing specificity, FHL1, FHL4, and ACT mRNAs are undetectable in BMMs and osteoclasts while FHL3
mRNA is constitutively expressed throughout
the process but not induced by RANKL and
M-CSF (Figure 3C).
Endogenous FHL2 and TRAF6 interact in osteoclasts. Having discovered that overexpressed
Figure 1
TRAF proteins interact with FHL2. (A) FLAG-tagged TRAF2, TRAF4, and TRAF6 and HA- FHL2 and TRAF6 interact in transformed cells,
tagged FHL2 were cotransfected into 293T cells. Protein expression level was detected by we asked if the same endogenous proteins assoimmunoblot with anti-FLAG and anti-HA antibodies. Cell lysates were immunoprecipitated ciate in authentic osteoclasts, and if so, whether
with anti-FLAG antibody and the immunoprecipitates immunoblotted with anti-HA antishort-term RANKL stimulation has an impact
body. A specific band appears in all TRAF-containing immunoprecipitates (arrow). (B) HAon the phenomenon. Thus, BMMs or osteotagged FHL2 and FLAG-tagged TRAF6 were cotransfected into 293T cells. Anti-HA antibody was used for immunoprecipitation and anti-FLAG antibody for immunoblotting. (C) clasts were serum- and cytokine-starved for 3
The same cells described in B were subjected to immunofluorescent microscopy using an hours and then treated with RANKL or vehicle
anti-FLAG rabbit polyclonal antibody and FITC-labeled secondary antibody (green reac- for 30 minutes. Immunoblotting of TRAF6
tion product) or anti-HA monoclonal antibody and TRITC-labled secondary antibody (red immunoprecipitates with anti-FHL2 antibody
reaction product). FHL2/TRAF6 colocalization was documented by simultaneous expo- establishes that the 2 proteins associate in
sure yielding the yellow reaction product (overlay). Magnification: ×200.
osteoclasts in a manner not impaired by acute
RANKL exposure (Figure 4A). The intracellular
association of TRAF6 and FHL2 is buttressed
To confirm the interaction between the 2 signaling molecules, we by their colocalization in mature osteoclasts as documented by
once again used 293T cells transfected with TRAF6-FLAG and immunofluorescent microscopy (Figure 4B).
FHL2-HA, in this instance immunoprecipitating HA and immuFHL2 blocks RANK /TRAF6 association. The fact that FHL2 assonoblotting FLAG. Once again, FHL2 coimmunoprecipitates with ciated with TRAF6 raised the possibility that formation of this
TRAF6 (Figure 1B). Furthermore, the intracellular association of complex on RANK blunts RANK/TRAF6 signaling. We tested this
TRAF6 and FHL2, when overexpressed in 293T cells, is evident by concept by first establishing that both TRAF6 (Figure 5A) and
immunofluorescent microscopy (Figure 1C).
FHL2 (Figure 5B) associate with RANK when overexpressed in
All domains of FHL2 are required to interact with TRAF6. Various com- 293T cells. TRAF6/RANK recognition is enhanced in the absence
binations of LIM domains of FHL2 are required to associate with of FHL2 in authentic preosteoclasts, indicating that the LIM
individual binding partners. For example, deletion of any FHL2 domain protein may blunt osteoclastogenic signals (Figure 5C).
LIM domain, including its half N terminal moiety, obviates associaFHL2 modulates NF-kB activity. Its association with TRAF6 in
tion with the β1A integrin subunit (13). To detail the components osteoclasts suggests FHL2 may participate in osteoclast function.
of FHL2 that mediate its recognition of TRAF6, we individually Because the RANK/TRAF6 complex signals via NF-κB, we asked
deleted each of its LIM domains and transfected the constructs, whether FHL2 has an impact on this transcription complex. To
as HA-tagged proteins, into 293T cells. In each circumstance, the determine the impact of FHL2 on NF-κB in authentic osteoclasts,
cells were also transfected with TRAF6-FLAG (Figure 2A). Anti-HA we turned to nuclear translocation of NF-κB, a requisite event in
immunoprecipitates were immunoblotted with anti-FLAG anti- its transcriptional activity. WT or FHL2–/– BMMs were exposed
body. Once again, the full-length proteins interact, but deletion of to RANKL and M-CSF for 3 days, starved for 3 hours, and once
any complete LIM domain or the N terminal half domain of FHL2 again exposed to RANKL. Nuclear proteins were extracted, at 0,
ablates this association. We then turned to the domain(s) of TRAF6 5, 15, and 30 minutes, and immunoblot was performed with an
required to interact with FHL2. Thus, we transfected 293T cells antibody to the p65 NF-kB subunit. As seen in Figure 6A, RANKL
with FLAG-tagged full-length TRAF6 or NH2 terminal deletion treatment induces more rapid and profound p65 nuclear transloconstructs lacking the ring domain (TRAF6-NR) or containing only cation in FHL2–/– than in WT cells.
the TRAF domain (TRAF6C). As seen in Figure 2B, the products of
To determine the transcriptional consequences of FHL2-restricteach TRAF6 construct immunoprecipitate with FHL2. Thus, the ed NF-κB activation, we assessed RANKL stimulation of selective
TRAF domain of TRAF6 suffices for its recognition of FHL2.
NF-κB–responsive genes in WT and FHL2-deleted preosteoclasts
FHL2 is specifically expressed during osteoclast differentiation in (Figure 6B). In fact, RANKL-induced expression of IκBα and TNF-α
vitro. We next asked if FHL2 is expressed in authentic osteo- in mRNA, both of which are the products of NF-κB target genes,
clasts in vitro. To this end, we cultured WT and FHL2–/– bone is enhanced in the cells lacking the LIM protein. On the other
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predicted that overexpression of the protein would
exert the opposite effect,
namely, blunted maturation and spreading
of bone resorptive cells.
As shown in Figure 8,
control BMMs exposed
to 50 ng/ml RANKL but
not those overexpressing
FHL2 differentiate into
characteristic osteoclasts.
At 100 ng/ml RANKL,
the FHL2-transduced
Figure 2
FHL2 and TRAF6 domains required for coassociation. (A) FHL2 deletion constructs were generated by muta- cells begin to undergo
genesis of full-length FHL2. FLAG-tagged TRAF6 and HA-tagged FHL2 constructs were cotransfected into 293T osteoclastogenesis, but
cells. Anti-HA antibody was used for immunoprecipitation and anti-FLAG antibody for immunoblotting. Deletion the polykaryons failed
of any LIM domain of FHL2 abolishes its interaction with TRAF6. The diagram defines ∆ mutants. (B) TRAF6 to assume the spread
constructs were generated by PCR. FLAG-tagged full-length TRAF6 (TRAF6-full), ring domain–deleted TRAF6 configuration apparent
(TRAF6-NR), and the complete TRAF domain (TRAF6C) were cotransfected with HA-tagged FHL2 into 293T in cells bearing empty
cells. Anti-HA antibody was used for immunoprecipitation and anti-FLAG antibody for immunoblotting.
vector. Spreading of
F H L 2 - ove r e x p r e s s i n g
osteoclasts is evident in
hand, TNF-α, which, like RANKL, is a TNF superfamily member, cultures containing 200 ng/ml RANKL, but even in this circumfails to substantially distinguish p65 translocation in FHL2–/– pre- stance, many cells remain unspread and the characteristic osteoosteoclasts relative to WT, establishing specificity of RANKL in clasts are smaller than control.
the FHL2 osteoclastogenic signaling pathway (Figure 6C).
FHL2-deficient osteoclasts undergo early apoptosis. The osteoclast is a
Finally, we reasoned that if its absence enhances NF-κB sig- terminally differentiated cell and as such enjoys a defined life span.
naling, the opposite should obtain in osteoclasts overexpress- This being the case, one would predict that cells reaching terminal
ing FHL2. To test this hypothesis, we retrovirally transduced differentiation rapidly would also initiate early apoptosis. In fact,
WT BMMs with an FHL2 expression plasmid or empty vector. by day 4 of culture, programmed cell death is increased more than
The cells were treated with M-CSF plus increasing amounts 2-fold in osteoclasts lacking FHL2 (Figure 9A). In keeping with this
of RANKL for 4 days and then assayed for RANKL-dependent observation, caspase 3 is activated earlier during the osteoclastoNF-κB activity. In keeping with a central role for the transcrip- genic process in FHL2–/– as compared with WT cells (Figure 9B).
tion complex in TRAF6-stimulated osteoclast formation and
function, overexpressed FHL2 arrests RANKL-induced IκBα
phosphorylation (Figure 6D).
Absence of FHL2 accelerates osteoclast differentiation and cytoskeletal
organization. These data indicate that FHL2 may delay osteoclast
recruitment and/or function. To determine if this is so, we treated FHL2–/– and WT BMMs with increasing doses of RANKL and
M-CSF. After 4 days, the number of characteristic, well-spread
osteoclasts was substantially greater in cultures derived from
FHL2–/– mice than in those from WT mice (Figure 7, A and B).
The enhancement of osteoclast size and spreading is particularly
evident at lower concentrations of RANKL, indicating that FHL2
deficiency sensitizes osteoclasts to the cytokine.The accelerated
rate of FHL2–/– osteoclast precursor differentiation is substantiated by increased expression of the 2 osteoclastogenic markers,
NFAT2 and cathepsin K (Figure 7C).
The propensity of FHL2 –/– osteoclasts to spread suggests
enhanced organization of their cytoskeleton. To determine if
this is so, we generated osteoclasts on dentin. Similarly to their Figure 3
–/–
appearance on plastic (Figure 7A), FHL2-deficient osteoclasts FHL2 is induced during osteoclastogenesis. (A) WT and FHL2 (KO)
BMMs
were
cultured
in
M-CSF
and
RANKL
for
up
to
4
days.
FHL2
on the resorptive substrate are larger than WT and have more
mRNA expression was determined by RT-PCR. GAPDH mRNA
pronounced actin rings, a critical hallmark of cytoskeletal orgaserved as loading control. (B) BMMs and osteoclasts, treated as in
nization (Figure 7D).
A, were lysed, and FHL2 expression was determined by immunoblot.
Overexpression of FHL2 attenuates osteoclast differentiation and β-actin served as loading control. (C) BMMs were treated with M-CSF
spreading. Given our findings that FHL2 deletion accelerates and RANKL for up to 4 days, and FHL family member mRNAs were
osteoclast differentiation and cytoskeletal organization, we determined by RT-PCR.
2744
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Figure 4
FHL2 interacts with TRAF6 in osteoclasts. (A) WT BMMs and
day 4 osteoclasts were starved for 3 hours and maintained
with and without RANKL (100 ng/ml) for 30 minutes. TRAF6
was immunoprecipitated from lysates and the immunoprecipitate blotted with anti-FHL2 or anti-TRAF6 antibodies. Lysate
content of the 2 proteins was determined by immunoblot. (B)
Mature osteoclasts (day 5) were subjected to immunofluorescent microscopy using an anti-TRAF6 rabbit polyclonal antibody and FITC-labeled secondary antibody (green reaction
product) or anti-FHL2 monoclonal antibody and TRITC-labled
secondary antibody (red reaction product). FHL2/TRAF6 colocalization was documented by simultaneous exposure yielding
the yellow reaction product (overlay). Magnification: ×200.

Absence of FHL2 enhances osteoclast resorptive activity. To determine
whether acceleration of differentiation and cytoskeletal organization of FHL2–/– osteoclasts extends to the cells’ capacity to degrade
bone, we generated osteoclasts from mutant and WT BMMs, on
dentin, for 4 days. Figure 10, A and B, shows that resorptive lacuna formation by FHL2-deficient osteoclasts during this period is
enhanced approximately 10-fold relative to that in WT.
These data substantiate stimulated net resorptive activity in
the absence of FHL2 in vitro. Together with the fact that RANKL
induces FHL2 expression by osteoclasts in vivo, they also suggest that FHL2-deficient mice, treated with the cytokine, would
resorb bone more aggressively than their WT counterparts. In
fact, tartrate-resistant acid phosphatase 5b (TRACP 5b) serum
levels of FHL2 –/– mice treated with RANKL for 7 days are
increased 4-fold relative to those of WT (Figure 10C). Reflecting this enhanced resorptive activity, trabecular bone volume of
RANKL-treated mutant mice is approximately one-third that of
their WT counterparts (Figure 10D). On the other hand, there
is no significant difference in bone mass between PBS-injected
WT and mutant mice.
FHL2 is expressed only in activated osteoclasts in vivo. The lack of
significant change in bone mass in PBS-injected FHL2–/– mice
challenges the relevance of the protein in basal osteoclast function. To address this issue, we assessed FHL2 expression by
osteoclasts in vivo. In fact, osteoclasts in naive WT mice do not
contain detectable immunoreactive protein (data not shown).
Because osteoclasts lacking NF-κB–inducing kinase, when
maintained in culture, reflect the activated and not basal state
of their in vivo counterparts (14), we asked whether the same
obtain regarding FHL2–/– bone resorptive cells. Hence we injected soluble RANKL (100 µg/day) or PBS for 7 days into WT and
FHL2–/– mice and once again immunostained histological sections with anti-FHL2 mAb. Similarly to naive WT mice, those
receiving PBS contain no osteoclast-residing immunoreactive FHL2 (Figure 11A). In contrast, numerous FHL2-expressing osteoclasts are present in the RANKL-treated animals. No
immunostaining is detectable in megakaryocytes, the bones of
FHL2–/– mice, or second antibody–exposed sections of RANKLtreated animals (not shown).
The fact that FHL2 is restricted to activated osteoclasts, in
vivo, suggests that expression of the protein by these cells may
also be abundant in diseases of accelerated bone resorption. We
therefore generated a murine model of inflammatory arthritis, which, like that affecting humans, is characterized by peri-

articular osteolysis (15). As seen in Figure 11B, joint-residing
osteoclasts in mice with inflammatory arthritis also contain
an abundance of immunoreactive FHL2. Documenting that
absence of FHL2 enhances bone resorption in the context of
this disease, serum TRACP 5b levels are substantially greater
in FHL2 –/– than in WT arthritic mice (Figure 11C). On the
other hand, FHL2 does not impact the numbers of osteoclasts
in naive mice and those treated with RANKL or afflicted with
inflammatory arthritis (data not shown). Consistent with cytoskeletal changes, therefore, the accelerated bone resorption in
the mutant animals reflect stimulated osteoclast activity rather
than enhanced recruitment.
Discussion
The discovery in 1998 that RANKL is the key osteoclastogenic
cytokine positioned it as a principal anti–bone resorptive target
(2). In fact, arrest of RANK signaling has proven effective treatment for postmenopausal osteoporosis (16). Thus, attention has
turned to modulating RANKL’s consequent intracellular signals as
a reasonable therapeutic strategy.

Figure 5
FHL2 inhibits TRAF6/RANK association in osteoclasts. FLAG-tagged
TRAF6, FLAG-tagged FHL2, and HA-tagged RANK were cotransfected, in various combinations, into 293T cells. Protein expression was
determined by anti-FLAG or anti-HA antibodies. Anti-FLAG antibody
was used for immunoprecipitation and anti-HA for immunoblotting. (A)
TRAF6 interacts with RANK. (B) FHL2 interacts with RANK. (C) After
4 days of exposure to M-CSF and RANKL, WT and FHL2–/– cells were
lysed. Equal amounts of lysate were immunoprecipitated with antiTRAF6 antibody and the immunoprecipitate blotted with anti-RANK or
anti-TRAF6 antibodies. Total cell lysate content of RANK, TRAF6, and
FHL2 were determined by immunoblot.
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Figure 6
FHL2 modulates NF-κB activity. WT and FHL2–/– BMMs were cultured with M-CSF and RANKL. On day 3, the cells were starved for 3
hours and then stimulated with RANKL (100 ng/ml) for up to 2 hours. (A) Nuclear proteins were extracted and NF-κB subunit p65 content
was determined by immunoblot. α-Nucleophosmin served as loading control. (B) IκBα and TNF-α mRNA expression was determined by
RT-PCR. GAPDH mRNA served as loading control. (C) WT and FHL2–/– BMMs were cultured with M-CSF and RANKL. On day 3, the cells
were starved for 3 hours and then stimulated with TNF-α (10 ng/ml) at 0, 5, 15, and 30 minutes. Nuclear proteins were extracted, and NF-κB
subunit p65 content was determined by immunoblot. α-Nucleophosmin served as loading control. (D) WT BMMs were retrovirally transduced
with empty vector (PMX) or vector expressing FHL2 and selected with blasticidin S, hydrochloride for 3 days. Selected cells were starved for
3 hours and stimulated with RANKL (100 ng/ml) for up to 30 minutes. Phosphorylated (p) and total (T) IκBα were determined by immunoblot.
β-actin served as loading control.

RANKL’s receptor, RANK, is a component of the TNF receptor superfamily and, like all other members, has a cytoplasmic
domain that associates with TRAFs (17). These adaptor molecules
regulate cytokine signaling by linking TNF family receptors with
downstream protein kinases, ubiquitin ligases, and other effector
proteins (17). A total of 6 mammalian TRAFs are in hand, and all
but TRAF4 recognize RANK. RANK binds TRAFs 1, 2, 3, and 5 at
a multiple TRAF-binding site in its carboxyl terminal region (18).
In contrast, TRAF6 targets a separate region of RANK, a domain
essential for RANKL’s effect on the osteoclast (19).
We initiated this study with the aim of identifying cellular proteins that associate with TRAF4. Our rationale for this undertaking was the fact that, while TRAF4 is not known to bind any
recognized receptor, mice deficient in the protein have skeletal
malformations (20). Thus, our aim was to begin to delineate the
means by which TRAF4 regulates the skeleton by detailing molecules to which it complexes. To this end, we turned to a yeast
2-hybrid assay and discovered that TRAF4 associates with the
LIM domain–only protein, FHL2.
LIM domain proteins typically serve as adaptors and scaffolds
for multimolecular complexes (21, 22). They contain various combinations of 2 tandemly repeated zinc fingers with which they
recognize their binding partners. FHL2 belongs to a subgroup of
5 homologous LIM domain–only proteins consisting exclusively
of FHLs (23). It has been linked with tumorigenesis, cell differentiation, and nuclear receptor regulation (24). The protein, while
originally believed expressed exclusively in heart (23), is also found
in striated muscle (25) and, relevant to the present paper, in a
myeloid cell line (26). FHL2 is localized within both the cytoplasm
and the nucleus and shuttles between these compartments (24).
In the nucleus, FHL2 serves as a cell and promoter-specific transcriptional coactivator or corepressor through its interaction with
transcription factors such as the androgen receptor (27), activator
protein-1 (28), cAMP response element binding protein (CREB)
and CREM (29), and β-catenin (30, 31).
Each TRAF contains a TRAF domain, the carboxyl terminal
of which mediates protein/protein interactions (5). Because the
2746

TRAF domains of TRAF4 and TRAF6 diverge from those of the
other 4 family members, we reasoned they would recognize distinct partners. Indeed, TRAF6, via its TRAF domain, binds FHL2
and does so with apparently greater efficiency relative to expressed
protein than either TRAF2 or TRAF4. This selectivity of FHL2
by TRAF6 and the central role this latter adaptor protein plays
in osteoclast biology prompted us to focus on the interaction
between the 2 molecules and how they, in combination, regulate
the osteoclast. In fact, FHL2, specific among its subfamily of LIM
domain–only proteins, increases pari passu with osteoclast differentiation. FHL2 also binds and colocalizes with TRAF6 in the
differentiated cell and dose dependently inhibits its association
with RANK. Given the importance of TRAF6 in RANK signaling, these observations suggested that FHL2 may have an impact
on the osteoclast. To determine whether this is so, we turned to
FHL2–/– mice and discovered that absence of the protein accelerate osteoclast differentiation. We also found that apoptotic
changes appear in FHL2–/– osteoclasts earlier than in their WT
counterparts. Two possible explanations for the accelerated death
of these mutant cells present themselves. In the first instance,
RANKL induces apoptosis of osteoclast-like cells through TRAF6
(32), whose association with RANK is blunted by FHL2. Second,
osteoclasts are terminally differentiated and incapable of mitotic
activity. Because the absence of FHL2 prompts the cell to rapidly
reach its ultimate state of differentiation, the polykaryon will also
die earlier. This combination of accelerated differentiation and
early death suggests that the longevity of FHL2–/– osteoclasts mirrors that of WT cells, which is also consonant with the similarity
of osteoclast numbers in both genotypes in vivo.
NF-κB activation is an essential component of the osteoclastogenic process (33). Consistent with accelerated osteoclast precursor differentiation, nuclear translocation of the p65 subunit of the
transcription complex is enhanced in FHL2-deficient osteoclast
precursors. Moreover, FHL2 overexpression in osteoclasts blunts
RANKL-stimulated IκBα phosphorylation. Thus, arrest of TRAF6mediated NF-κB activation is likely to be an essential component
of the antiosteoclastogenic properties of FHL2.
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Figure 7
Absence of FHL2 accelerates osteoclast differentiation and cytoskeletal organization. (A) BMMs derived from WT and FHL2–/– mice were maintained
for 4 days in M-CSF and increasing concentrations of RANKL. The cells were then stained for TRAP activity to determine the relative numbers of characteristic spread osteoclasts (arrows). (B) Quantitative data derived from experiment detailed in A comparing the numbers of characteristic spread
osteoclasts (OCs) as a function of RANKL concentration. Inset shows characteristic spread and nonspread osteoclasts, respectively. *P < 0.05;
**P < 0.01. (C) BMMs derived from WT and FHL2–/– mice were maintained for up to 4 days in M-CSF plus RANKL. Equal amounts of lysate were
immunoblotted for NFAT2 and cathepsin K (CathK) content. β-actin serves as loading control. (D) WT and FHL2–/– BMMs were cultured on dentin
with M-CSF and RANKL. On day 4, the cells were fixed and actin ring formation was assessed by rhodamine-phalloidin staining. Magnification:
×200 (A) and ×600 (B and D).

Despite the central role enjoyed by TRAF6 in regulating the
osteoclast, its precise impact on the resorptive cell is controversial because of the varied phenotypes of mice lacking the adaptor
protein. As expected, TRAF6–/– mice are osteopetrotic regardless of
strain and one group posits that their failure to resorb bone represents an absence of osteoclasts (9). Alternatively, another laboratory claims that TRAF6-deficient osteoclasts are generated but are
dysfunctional, as they do not attach to bone, a likely cytoskeletal
defect (8). While this discrepancy remains to be resolved, it may
relate to the fact that RANKL has an impact not only on commitment of macrophages to the osteoclast phenotype but also on activation of mature osteoclasts. In this regard, Armstrong et al. report
that TRAF6 is essential for osteoclast cytoskeletal organization
and resorptive function but that partial redundancy exists among
the various TRAFs in RANKL-mediated osteoclast differentiation
(34). In fact, FHL2 has an impact on the osteoclast cytoskeleton as
evidenced by either its deletion or excess. Specifically, osteoclasts
lacking FHL2 have accelerated formation of large actin rings. This
cytoskeletal structure isolates the resorptive microenvironment
from the general extracellular space and is essential for optimal
bone degradation, as it is absent in disorders of osteoclast function
such as that characterizing deletion of the β3 integrin (35). In this
regard, FHL2 expression by osteoclasts is similar to that of the β3

integrin by endothelial cells (36–38). Both proteins are abundant
in culture but absent in naive cells in vivo, only to appear in states
of cellular activation. These observations underscore the likelihood that discrepancies between gene expression in vitro and in
naive animals represent a global activating effect of culture. Such a
circumstance is also evident as regards the osteoclastogenic capacity of NF-κB–inducing kinase–deficient mice (14).
Similar to other molecules, such as SHIP-1 (39), which physiologically restrain osteoclast function, deletion of FHL2 results in
exaggerated cytoskeletal organization leading to hyperresorptive
osteoclasts and, in vivo, a deficit of bone mass following RANKL
treatment. In contrast, yet also in keeping with inhibition of
TRAF6-mediated differentiation and cytoskeletal organization,
FHL2 overexpression desensitizes osteoclast precursors to RANKL,
consequently limiting their differentiation and the ability of the
polykaryons to spread effectively.
These studies expand our knowledge of the RANK signaling
pathway and underscore the importance of TRAF6-associated proteins in regulating the osteoclast. Finally, FHL2 joins a growing
collection of molecules not suspected of participating in skeletal
biology that ultimately prove to be modulators of bone cell function and thus potential therapeutic targets, particularly in states
of accelerated resorption.
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Figure 8
FHL2 overexpression attenuates osteoclast differentiation and spreading. BMMs were retrovirally transduced with empty vector or vector expressing FHL2
and selected with blasticidin S, hydrochloride for 3
days. Selected cells were stimulated with M-CSF and
increasing doses of RANKL for 4 days after which the
cultures were stained for TRAP activity. Arrows point
to nonspread osteoclasts. Magnification: ×400.

Methods
Mice. FHL2–/– and WT mice on the hybrid Black Swiss-129-SV/J background
were the products of heterozygous crosses (40). Animals were housed in the
animal care unit of the Department of Pathology, Washington University
School of Medicine, and were maintained according to guidelines of the
Association for Assessment and Accreditation of Laboratory Animal Care.
All animal experimentation was approved by the Animal Studies Committee of Washington University School of Medicine.
Reagents. Recombinant murine M-CSF was from R&D Systems. Murine
glutathione-S-transferase–RANKL was expressed in our laboratory as
described previously (4). Anti-HA antibody was obtained from Covance
Research Products. Anti-TRAF6 and anti-NFAT2 antibodies were obtained
from Santa Cruz Biotechnology Inc. Antiactivated and anti–total caspase 3
antibodies were obtained from Cell Signaling Technology. All other chemicals were obtained from Sigma-Aldrich.
Two-hybrid library screening. A full-length TRAF4 coding sequence was
cloned into pGBT9 (BD Biosciences — Clontech) to generate the pGBT9/
TRAF4 bait plasmid. The mouse embryo pACT2 cDNA library (a generous
gift from Xu Cao, University of Alabama at Birmingham, Birmingham,
Alabama, USA) was screened according to the manufacturer’s instructions
(BD Biosciences — Clontech).
Plasmids. TRAF2, TRAF4, and TRAF6 cDNA were obtained by RT-PCR and
PCR from a murine primary osteoblast cDNA library generated in our laboratory. All TRAFs were coupled to FLAG tag (Sigma-Aldrich) at the C terminal in PcDNA3 vector (Invitrogen Corp.). RANK-HA plasmid was generated
in our laboratory. FHL2 cDNA was recovered from the yeast 2-hybrid assay
and was linked with either FLAG or HA at C terminal in PcDNA3 vector.
Immunoprecipitation and Western blot. FLAG-tagged full-length and
truncated TRAF6, FLAG tagged FHL2, and HA-tagged full-length and

truncated FHL2 cDNAs were subcloned into the mammalian expression vector pcDNA3 (Invitrogen Corp.). 293T cells were transfected
with expression constructs using Fugene 6 as the transfection reagent
according to the manufacturer’s instructions (Promega). Cells were lysed
48 hours after transfection, and lysates were immunoprecipitated and
immunoblotted with anti-FLAG or anti-HA antiserum. Anti-TRAF6,
anti-FHL2, and anti-RANK antibodies were used to detect endogenous
protein-protein interaction. Nuclear p65 translocation experiments were
performed by using lysates of preosteoclasts generated by exposure of
BMMs to M-CSF and RANKL for 3 days.
Immunofluorescence. Intracellular TRAF6 and FHL2 were labeled with
fluorescent markers as described (41). In brief, cells were fixed with 3%
paraformaldehyde in PBS for 20 minutes. Free aldehyde groups were
quenched with 50 mM NH4Cl in PBS for 10 minutes. Nonspecific binding was blocked by incubation in PBS containing 0.2% bovine serum
albumin and 0.05% saponin (PBSBS) for 15 minutes. The cells were then
incubated with primary antibodies in PBSBS for 1 hour. Primary antibody binding was visualized using fluorescent dye–conjugated secondary
antibodies (Jackson ImmunoResearch Laboratories Inc.) in PBSBS for
45 minutes. Immunofluorescence analysis was performed using a Nikon
fluorescence microscope equipped with a CCD camera. Primary antibodies used include rabbit anti-FLAG (Sigma-Aldrich), monoclonal anti-HA
(Covance Research Products), monoclonal anti-FHL2, and polyclonal
anti-TRAF6 (Santa Cruz Biotechnology Inc.).
Primary cells and cell lines. Macrophages/osteoclast precursors and osteoclasts were generated from bone marrow precursors as described (42). C2C12
and 293T cells were obtained from ATCC and were maintained as described.
Characterization of osteoclasts. BMMs were cultured in 96-well cell culture
dishes in the presence of M-CSF (10 ng/ml) and RANKL (100 ng/ml or

Figure 9
FHL2-deficient osteoclasts undergo early apoptosis. WT and FHL2–/– BMMs were cultured in M-CSF and RANKL. (A) The magnitude of
apoptosis was measured by ELISA 4 days later. **P < 0.01. (B) Activated and total caspase 3 were measured by immunoblot with time.
β-actin served as loading control.
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Figure 10
Absence of FHL2 enhances osteoclast resorptive
activity and RANKL-stimulated bone loss. (A) WT
and FHL2–/– BMMs were cultured on dentin with
M-CSF and RANKL. Resorption lacuna formation
was examined on day 4 by Coomassie brilliant
blue staining. Magnification: ×200. (B) Quantitative analysis of experiment detailed in A. Pit area
(%), percentage of dentin surface occupied by
resorption lacunae. (C) WT and FHL2–/– mice were
administered 100 µg RANKL subcutaneously for 7
days. Serum TRACP 5b levels were determined by
ELISA. (D) WT and FHL2–/– mice were administered
PBS (control) or RANKL (100 µg) daily for 7 days.
The tibiae were recovered on day 9 and trabecular bone volume (BV/TV) determined by micro-CT.
*P < 0.05; **P < 0.01.

doses detailed in figure legends). Media were changed on day 3. Osteoclast-like cells were characterized by staining for tartrate-resistant acid
phosphatase (TRAP) activity. The number of osteoclasts was counted as
described previously (42). The characteristics of spread as compared to
nonspread osteoclasts are illustrated in Figure 7B.
RNA extraction and amplification by RT-PCR. BMMs were exposed to
M-CSF and RANKL for various times as detailed in figure legends.
RNA purification and RT-PCR conditions were as described previously (42). The oligonucleotide primers used are as follows: FHL1,
5′-GTTTCACCGCTGTGGAGGAC, 3′-GAGGGAGGGAGGGAGCAAAG; FHL2, 5′-CCCCATTAGTGGTCTGGGTG, 3′-CCAGGGCAGC A AG AG G A AG C ; F H L 3 , 5 ′ - G C G C C C C AT C G TAG G AC T C G ,
3′-CGTTCTAGGGAGGGGTTGGG; FHL4, 5′-GGGTGCAAGAACCCCATCAC, 3′-GGAGCAGCTTCACAGAGGTG; ACT, 5′GCCTGCTGTGCACAGACTGC, 3′-GGGTTTGGTGCAGGCTGCAC.
Bone resorption. Osteoclasts were generated on whale dentin slices from
BMMs under conditions described above. After 4 days the cells were
stained for TRAP activity. For actin-ring staining, cells were fixed in 4%
paraformaldehyde, permeabilized in 0.1% Triton X-100, rinsed in PBS, and
immunostained with Alexa 488 phalloidin (Invitrogen Corp.). To quantitate resorption lacunae, cells were removed from the dentin slices with

0.5 M ammonium hydroxide and mechanical agitation. Dentin slides were
stained with Coomassie brilliant blue.

Figure 11
FHL2 is expressed only in activated osteoclasts. (A) WT mice were
administered PBS or RANKL (100 µg/day) for 7 days. On day 9, histological sections of tibiae were stained for TRAP activity (red reaction
product) or immunostained using an anti-FHL2 mAb. Osteoclasts in
the RANKL-treated, but not PBS-treated, mice stained positive for the
brown reaction product. (B) Serum transfer inflammatory arthritis was
induced in WT mice. After 7 days, histological sections of the inflamed
joints were immunostained for FHL-2, which is present in osteoclasts.
(C) WT and FHL2–/– mice were administered arthrogenic serum to
induce inflammatory arthritis or PBS as control. Serum TRACP 5b
levels were measured at days 0, 7, and 14. *P < 0.05 vs. WT serum.
Magnification: ×400.
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Cell stimulation and immunoblotting. For NF-κB signaling experiments, primary macrophages were infected with empty vector or FHL2-expressing
retrovirus (43). Infected cells were selected by blasticidin S, hydrochloride
(BSR) for 3 days and starved for 3 hours. RANKL (100 ng/ml) was added
to the media, cells were lysed at 0, 5, 15, and 30 minutes, and the lysate was
subjected to immunoblotting.
RANKL-stimulated bone loss in vivo. RANKL (100 µg per mouse per day)
or PBS, as control, was injected subcutaneously once per day for 7 days.
Two days after the final injection, mice were sacrificed by CO 2 narcosis
and the tibias, devoid of soft tissue, were used to determine trabecular
bone volume by micro-CT.
Cell death detection assay. Cell death detection assay was performed according to the protocol of the Cell Death Detection ELISA kit (Roche Diagnostics
Corp.). In brief, WT and FHL2–/– (KO) BMMs were cultured in 48-well plates
(1.5 × 104 cells/well) in M-CSF and RANKL (100 ng/ml) for 4 days. On days 4
and 5, cells were lysated and centrifuged, respectively, at 200 g for 10 minutes.
Supernants (20 µl) were mixed with 80 µl immunoreagent for 2 hours with
shaking at room temperature. The solution was aspirated, and the wells were
washed 3 times with 300 ml incubation buffer. Substrate solution (100 µl)
was added to each well and incubated on a plate shaker at 250 rpm until
color development was complete. The absorbance was read at 405 nm.
Immunohistochemical staining. The PBS- and RANKL-injected FHL2 WT
and FHL2–/– mice trabecular bone tissues were paraffin embedded and
cut into 5-µm sections. Samples were briefly treated with hydrogen peroxide to block endogenous peroxidase. Antigen retrieval method was
used. To lessen nonspecific binding, the samples were blocked with a
mouse Ig reagent. Monoclonal FHL2 antibody was diluted 1:100 and
incubated at 4°C overnight, followed by incubation with biotinylated
anti-mouse second antibody using a Vectastain Elite ABC kit (Vector
Laboratories) according to the manufacturer's protocol. The samples
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